Concentra Group Holdings Parent Inc. raised its full-year 2026 revenue guidance to a range of $2.325 billion to $2.375 billion and adjusted EBITDA to $485 million to $495 million, the company said in its second-quarter earnings announcement. The guidance increase came alongside a leadership transition scheduled for November 1, when Matt DiCanio will assume the role of president and chief executive officer.
Keith Newton, the current chief executive, will transition to executive chairman. Concentra did not specify whether Newton remains on the board or what responsibilities the executive chairman role carries. The company operates urgent care clinics, occupational health services, and physical therapy locations across Canada and the United States.
The midpoint of Concentra's raised revenue guidance stands at $2.35 billion, roughly 3 percent above the low end of its prior range. Adjusted EBITDA guidance at the midpoint is $490 million. The company did not disclose which business segments drove the upward revision or whether the increase comes from organic growth, acquisitions, or both.
DiCanio joins from a role within the Concentra organization; the company did not describe his previous title or tenure. Newton's shift to executive chairman is a common transition structure in private equity-backed companies, where departing chief executives often retain board seats during leadership changes. Concentra is owned by Onex Corporation, a Toronto-based investment firm.
CEO transitions at health services platforms typically occur before or after earnings, rarely concurrent with guidance increases. The board and ownership announced the parallel move together.
Concentra's raised guidance comes with stronger-than-expected mid-year performance but the margin on adjusted EBITDA stayed essentially flat year-over-year in guidance range terms. If the company delivers at the midpoint of both ranges, adjusted EBITDA margin would be roughly 20.9 percent of revenue, consistent with prior expectations rather than demonstrating margin expansion.
What matters next is whether Concentra's third and fourth quarter results track the raised guidance or whether the company faces headwinds that force another revision before DiCanio's November 1 start date.
